NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis → Urgent: Protect Your Investments from a Chinese Invasion (From Behind the Markets) (Ad) Free EDIT Stock Alerts $7.45 +0.01 (+0.13%) (As of 10:51 AM ET) Add Compare Share Share Today's Range$7.37▼$7.5250-Day Range$7.03▼$11.0752-Week Range$6.08▼$11.91Volume210,546 shsAverage Volume1.83 million shsMarket Capitalization$609.48 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Editas Medicine alerts: Email Address Editas Medicine MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside102.4% Upside$15.00 Price TargetShort InterestBearish17.03% of Shares Sold ShortDividend StrengthN/ASustainability-0.94Upright™ Environmental ScoreNews Sentiment0.60Based on 13 Articles This WeekInsider TradingSelling Shares$924,582 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.61) to ($2.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.69 out of 5 starsMedical Sector253rd out of 939 stocksBiological Products, Except Diagnostic Industry31st out of 156 stocks 3.3 Analyst's Opinion Consensus RatingEditas Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Editas Medicine has a forecasted upside of 102.4% from its current price of $7.41.Amount of Analyst CoverageEditas Medicine has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.03% of the outstanding shares of Editas Medicine have been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Editas Medicine has recently increased by 3.03%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEditas Medicine has received a 67.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Editas Medicine is -0.94. Previous Next 2.6 News and Social Media Coverage News SentimentEditas Medicine has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Editas Medicine this week, compared to 4 articles on an average week.Search InterestOnly 36 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows18 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $924,582.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Editas Medicine are expected to decrease in the coming year, from ($2.61) to ($2.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -3.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Editas Medicine Stock (NASDAQ:EDIT)Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Read More EDIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EDIT Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Moderate Buy" from AnalystsMarch 23, 2024 | americanbankingnews.comQ1 2024 Earnings Forecast for Editas Medicine, Inc. (NASDAQ:EDIT) Issued By Zacks ResearchMarch 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 22, 2024 | americanbankingnews.comEditas Medicine, Inc. Expected to Post FY2026 Earnings of ($2.80) Per Share (NASDAQ:EDIT)March 22, 2024 | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Expected to Earn FY2025 Earnings of ($1.72) Per ShareMarch 20, 2024 | americanbankingnews.comEditas Medicine, Inc. (NASDAQ:EDIT) Sees Significant Growth in Short InterestMarch 13, 2024 | seekingalpha.comEditas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)March 12, 2024 | seekingalpha.comEditas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)March 28, 2024 | Behind the Markets (Ad)Urgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.March 7, 2024 | fool.com1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.March 6, 2024 | seekingalpha.comEditas Medicine, Inc. (EDIT) TD Cowen 44th Annual Healthcare Conference (Transcript)March 4, 2024 | fool.com1 Beaten-Down Stock With 55% Upside, According to Wall StreetMarch 2, 2024 | fool.comWhy Editas Medicine Stock Soared as Much as 42% Higher This WeekMarch 1, 2024 | markets.businessinsider.comStrong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive OptimismFebruary 29, 2024 | markets.businessinsider.comHold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation PotentialFebruary 29, 2024 | finance.yahoo.comQ4 2023 Editas Medicine Inc Earnings CallFebruary 28, 2024 | msn.comEditas Medicine files for mixed shelf offeringFebruary 28, 2024 | marketwatch.comEditas Medicine Shares Rally After Reni-cel Study UpgradeFebruary 28, 2024 | msn.comEditas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32MFebruary 28, 2024 | markets.businessinsider.comHere's what Wall Street expects from Editas Medicine's earnings reportFebruary 28, 2024 | finance.yahoo.comEditas Medicine Inc (EDIT) Reports Improved Financials and Advances in Gene Editing TrialsFebruary 28, 2024 | msn.comEditas spikes as Vertex Pharma deal boosts Q4 toplineFebruary 28, 2024 | globenewswire.comEditas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business UpdatesFebruary 27, 2024 | benzinga.comEarnings Outlook For Editas MedicineFebruary 27, 2024 | msn.comEditas Medicine Q4 2023 Earnings PreviewFebruary 24, 2024 | finance.yahoo.comEDIT Mar 2024 7.000 putFebruary 24, 2024 | ca.finance.yahoo.comEDIT Mar 2024 12.000 callSee More Headlines Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/28/2024Next Earnings (Estimated)5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:EDIT CUSIPN/A CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees265Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+101.1%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,220,000.00 Net Margins-196.12% Pretax Margin-196.12% Return on Equity-42.95% Return on Assets-30.49% Debt Debt-to-Equity RatioN/A Current Ratio5.39 Quick Ratio5.39 Sales & Book Value Annual Sales$78.12 million Price / Sales7.81 Cash FlowN/A Price / Cash FlowN/A Book Value$4.27 per share Price / Book1.75Miscellaneous Outstanding Shares81,810,000Free Float80,014,000Market Cap$610.30 million OptionableOptionable Beta2.06 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Gilmore O'Neill M.D. (Age 59)President, CEO & Director Comp: $815.37kDr. Baisong Mei M.D.Ph.D., Senior VP & Chief Medical OfficerDr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board MemberDr. George McDonald Church Ph.D. (Age 70)Co-Founder & Scientific Advisory Board Member Dr. J. Keith Joung M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. David R. Liu Ph.D.Co-Founder & Scientific Advisory Board MemberDr. Linda C. Burkly Ph.D.Executive VP & Chief Scientific OfficerCristi BarnettCorporate Communications & Investor RelationsMs. Charlene Stern J.D.Ph.D., Executive VP & General CounselMs. Linea Aspesi (Age 54)Executive VP & Chief People Officer More ExecutivesKey CompetitorsTaysha Gene TherapiesNASDAQ:TSHAAlectorNASDAQ:ALECValnevaNASDAQ:VALNC4 TherapeuticsNASDAQ:CCCCNovavaxNASDAQ:NVAXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 74,351 shares on 3/11/2024Ownership: 10.343%Gilmore Neil O'neillSold 77,824 sharesTotal: $733,102.08 ($9.42/share)Baisong MeiSold 20,327 sharesTotal: $191,480.34 ($9.42/share)Virtu Financial LLCBought 73,886 shares on 2/26/2024Ownership: 0.090%Price T Rowe Associates Inc. MDSold 1,262 shares on 2/16/2024Ownership: 0.052%View All Insider TransactionsView All Institutional Transactions EDIT Stock Analysis - Frequently Asked Questions Should I buy or sell Editas Medicine stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" EDIT shares. View EDIT analyst ratings or view top-rated stocks. What is Editas Medicine's stock price target for 2024? 9 analysts have issued 12 month price objectives for Editas Medicine's shares. Their EDIT share price targets range from $9.00 to $20.00. On average, they expect the company's share price to reach $15.00 in the next year. This suggests a possible upside of 102.4% from the stock's current price. View analysts price targets for EDIT or view top-rated stocks among Wall Street analysts. How have EDIT shares performed in 2024? Editas Medicine's stock was trading at $10.13 at the beginning of 2024. Since then, EDIT stock has decreased by 26.9% and is now trading at $7.41. View the best growth stocks for 2024 here. When is Editas Medicine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our EDIT earnings forecast. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.29. The company earned $60 million during the quarter, compared to analyst estimates of $4.84 million. Editas Medicine had a negative net margin of 196.12% and a negative trailing twelve-month return on equity of 42.95%. The business's revenue was up 817.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.88) EPS. What ETFs hold Editas Medicine's stock? ETFs with the largest weight of Editas Medicine (NASDAQ:EDIT) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), iShares Genomics Immunology and Healthcare ETF (IDNA), Horizon Kinetics Medical ETF (MEDX), Direxion Moonshot Innovators ETF (MOON), Global X Genomics & Biotechnology ETF (GNOM) and AXS Green Alpha ETF (NXTE).WisdomTree BioRevolution Fund (WDNA) and What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS). When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. Who are Editas Medicine's major shareholders? Editas Medicine's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.36%), Vanguard Group Inc. (10.34%), Dimensional Fund Advisors LP (2.93%), Northern Trust Corp (1.07%), Charles Schwab Investment Management Inc. (0.84%) and Nuveen Asset Management LLC (0.79%). Insiders that own company stock include Baisong Mei, Bruce Eaton, Gilmore Neil O'neill, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson. View institutional ownership trends. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EDIT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.